GAD1 and migraine disorder: In addition, the large patient sample size allowed for a number of subgroup analyses to be conducted, including the currently presented analyses in populations by migraine type or with DTT migraine (MO, MDD, GAD, or prior CGRP pathway–targeted mAb exposure).